Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXS Astria Therapeutics	$5.57 +2.4%	$4.95	$3.56 ▼ $12.92	$314.34M	0.39	366,093 shs	1.35 million shs
ATYR aTyr Pharma	$5.03 -5.3%	$4.20	$1.48 ▼ $5.98	$447.69M	0.88	1.18 million shs	15.78 million shs
CLLS Cellectis	$1.45 -2.5%	$1.48	$1.10 ▼ $2.43	$80.60M	2.92	143,083 shs	50,843 shs
TSHA Taysha Gene Therapies	$2.38 -1.2%	$2.43	$1.05 ▼ $3.31	$510.90M	1.04	2.93 million shs	2.30 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXS Astria Therapeutics	0.00%	-4.95%	+12.53%	-2.28%	-38.04%
ATYR aTyr Pharma	0.00%	-3.64%	+18.08%	+60.70%	+502,999,900.00%
CLLS Cellectis	0.00%	-1.36%	+0.69%	+14.17%	-22.46%
TSHA Taysha Gene Therapies	0.00%	-3.25%	-13.45%	+23.32%	+16.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATXS Astria Therapeutics	1.7843 of 5 stars	3.6	1.0	2.1	1.7	0.0
ATYR aTyr Pharma	2.6799 of 5 stars	3.6	2.0	3.1	1.7	0.6
CLLS Cellectis	2.9846 of 5 stars	3.5	3.0	2.5	2.5	0.6
TSHA Taysha Gene Therapies	3.0034 of 5 stars	4.5	1.0	1.9	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXS Astria Therapeutics	3.25	Buy	$30.00	438.60% Upside
ATYR aTyr Pharma	3.14	Buy	$20.20	301.59% Upside
CLLS Cellectis	3.00	Buy	$4.00	175.86% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$8.00	236.13% Upside

Current Analyst Ratings Breakdown

Latest CLLS, TSHA, ATXS, and ATYR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	ATYR aTyr Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $25.00
6/13/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/10/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/4/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
6/3/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
6/2/2025	TSHA Taysha Gene Therapies	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $8.00
5/29/2025	TSHA Taysha Gene Therapies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/29/2025	TSHA Taysha Gene Therapies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$5.00 ➝ $6.00
5/29/2025	TSHA Taysha Gene Therapies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $9.00
5/19/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
5/16/2025	TSHA Taysha Gene Therapies	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $9.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	$3.97 per share	N/A
ATYR aTyr Pharma	$230K	1,946.39	N/A	N/A	$0.83 per share	6.06
CLLS Cellectis	$49.22M	1.64	N/A	N/A	$2.36 per share	0.61
TSHA Taysha Gene Therapies	$8.33M	61.33	N/A	N/A	$0.35 per share	6.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXS Astria Therapeutics	-$94.26M	-$1.87	N/A	N/A	N/A	N/A	-47.18%	-31.26%	8/11/2025 (Estimated)
ATYR aTyr Pharma	-$64.02M	-$0.81	N/A	N/A	N/A	N/A	-87.09%	-64.77%	8/12/2025 (Estimated)
CLLS Cellectis	-$36.76M	-$0.86	N/A	N/A	N/A	-114.82%	-62.55%	-21.19%	8/5/2025 (Estimated)
TSHA Taysha Gene Therapies	-$89.30M	-$0.34	N/A	N/A	N/A	-1,201.08%	-104.93%	-50.09%	8/11/2025 (Estimated)

Latest CLLS, TSHA, ATXS, and ATYR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	TSHA Taysha Gene Therapies	-$0.08	-$0.08	N/A	-$0.08	$1.48 million	$2.30 million
5/13/2025	Q1 2025	ATXS Astria Therapeutics	-$0.48	-$0.58	-$0.10	-$0.58	N/A	N/A
5/12/2025	Q1 2025	CLLS Cellectis	-$0.1540	-$0.18	-$0.0260	-$0.18	$12.71 million	$12.03 million
5/7/2025	Q1 2025	ATYR aTyr Pharma	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXS Astria Therapeutics	N/A	17.39	17.39
ATYR aTyr Pharma	0.01	7.79	7.79
CLLS Cellectis	0.44	1.67	1.67
TSHA Taysha Gene Therapies	0.77	5.35	5.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXS Astria Therapeutics	98.98%
ATYR aTyr Pharma	61.72%
CLLS Cellectis	63.90%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
ATXS Astria Therapeutics	4.50%
ATYR aTyr Pharma	3.70%
CLLS Cellectis	16.41%
TSHA Taysha Gene Therapies	3.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXS Astria Therapeutics	30	56.43 million	53.89 million	Optionable
ATYR aTyr Pharma	53	89.00 million	85.71 million	Optionable
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
TSHA Taysha Gene Therapies	180	214.66 million	206.55 million	Optionable

CLLS, TSHA, ATXS, and ATYR Headlines

Recent News About These Companies

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 4.3% - Here's What Happened

June 26 at 4:46 PM | marketbeat.com

Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Target Price at $7.57

June 24, 2025 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Here's What Happened

June 22, 2025 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9% - Here's Why

June 20, 2025 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages

June 19, 2025 | marketbeat.com

Equities Analysts Offer Predictions for TSHA FY2025 Earnings

June 16, 2025 | marketbeat.com

Millennium Management LLC Makes New Investment in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 12, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 10.5% - Time to Buy?

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Estimates TSHA FY2026 Earnings

June 11, 2025 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Down 5.9% - What's Next?

June 10, 2025 | marketbeat.com

Needham & Company LLC Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA)

June 10, 2025 | marketbeat.com

Taysha Gene Therapies Grants Stock Options to New Employees Under Inducement Plan

June 8, 2025 | nasdaq.com

Wellington Management Group LLP Purchases 122,402 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 7, 2025 | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

Squarepoint Ops LLC Has $366,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

June 6, 2025 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Major Shareholder Buys $2,062,500.00 in Stock

June 4, 2025 | marketbeat.com

Taysha Gene Therapies Releases TSHA-102 Clinical Program Updates

June 4, 2025 | insidermonkey.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Insider Buying Activity

June 4, 2025 | marketbeat.com

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data

June 4, 2025 | msn.com

Paul B. Manning Buys 750,000 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Stock

June 4, 2025 | insidertrades.com

Taysha Gene Therapies Highlights TSHA-102 Program Advancements for Rett Syndrome at 2025 IRSF Scientific Meeting

June 3, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS, TSHA, ATXS, and ATYR Company Descriptions

Astria Therapeutics NASDAQ:ATXS

$5.57 +0.13 (+2.39%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.58 +0.01 (+0.18%)

As of 06/27/2025 07:30 PM Eastern

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

aTyr Pharma NASDAQ:ATYR

$5.03 -0.28 (-5.27%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.09 +0.06 (+1.19%)

As of 06/27/2025 07:59 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Cellectis NASDAQ:CLLS

$1.46 -0.02 (-1.53%)

As of 06/27/2025 04:00 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Taysha Gene Therapies NASDAQ:TSHA

$2.38 -0.03 (-1.24%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.36 -0.02 (-0.84%)

As of 06/27/2025 05:13 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time